Ridgetech Inc. Ordinary Shares (RDGT)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as Graham would: first ask whether the business earns money, then whether the price offers protection. Ridgetech wholesales pharmaceuticals and healthcare products in China through offline and online segments, with only 64 employees. The data show a company at $0.86 on 2026-10-13 and a market capitalization of just $1.7 million. FairStock's calculations give a P/E of -0.05, P/B of 0.02, ROE of -3.55%, and ROCE of -1.75%. That combination says the market is pricing this near liquidation or worse. The absence of debt, with D/E at 0.00, is a genuine positive; a debt-free balance sheet gives time. But the financial quality signals are poor: a Piotroski F-Score of 2/9 and Altman Z-Score of -0.64 point to distress. The 52-week range of $0.67 to $760.50 implies extreme volatility, not a stable compounding machine. Revenue and profit growth are N/A, and the Lynch category is none because only 0 years of filed results are available, when 3 are needed. Without a multi-year record, I cannot judge earning power or a moat. The P/B of 0.02 may look like a bargain, but Graham warned that assets can evaporate when operations bleed. For a value investor, the only real attraction is the asset discount and debt-free status; the lack of earnings, track record, and financial strength keeps this in the speculative pile, not the compounding pile.

In plain English: Ridgetech sells prescription and over-the-counter medicines, supplements, traditional Chinese medicine, and medical devices to other businesses in China, both online and offline. The numbers show a very small company that is losing money and scores poorly on financial strength, with no usable growth history. Its shares look extremely cheap compared with its accounting assets, but that discount reflects serious doubts about whether the business can earn a profit.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer